Sotera Health (NASDAQ:SHC) Receives $16.08 Consensus Target Price from Analysts

Sotera Health (NASDAQ:SHC) has been assigned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $16.08.

A number of brokerages have recently weighed in on SHC. Citigroup raised their target price on Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Royal Bank of Canada reiterated an “outperform” rating and set a $17.00 target price on shares of Sotera Health in a research report on Thursday, November 21st. Finally, The Goldman Sachs Group initiated coverage on shares of Sotera Health in a report on Friday, December 6th. They issued a “neutral” rating and a $14.00 price target for the company.

Sotera Health Price Performance

Shares of Sotera Health stock opened at $13.63 on Friday. The firm has a market cap of $3.86 billion, a P/E ratio of 54.52 and a beta of 1.96. The firm’s 50-day simple moving average is $13.98 and its 200-day simple moving average is $14.37. Sotera Health has a twelve month low of $10.71 and a twelve month high of $17.44. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88.

Sotera Health (NASDAQ:SHC) last announced its quarterly earnings results on Tuesday, November 5th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The company had revenue of $285.47 million during the quarter, compared to analyst estimates of $278.64 million. During the same period in the prior year, the firm earned $0.18 EPS. Sotera Health’s quarterly revenue was up 8.5% compared to the same quarter last year. As a group, research analysts expect that Sotera Health will post 0.61 EPS for the current fiscal year.

Institutional Trading of Sotera Health

A number of hedge funds and other institutional investors have recently made changes to their positions in SHC. True Wealth Design LLC bought a new stake in Sotera Health during the third quarter worth about $32,000. GAMMA Investing LLC raised its stake in shares of Sotera Health by 125.0% during the 3rd quarter. GAMMA Investing LLC now owns 2,988 shares of the company’s stock worth $50,000 after purchasing an additional 1,660 shares in the last quarter. Point72 DIFC Ltd raised its stake in shares of Sotera Health by 556.6% during the 2nd quarter. Point72 DIFC Ltd now owns 6,540 shares of the company’s stock worth $78,000 after purchasing an additional 5,544 shares in the last quarter. Capital Performance Advisors LLP acquired a new stake in shares of Sotera Health in the 3rd quarter valued at approximately $91,000. Finally, Acadian Asset Management LLC grew its stake in shares of Sotera Health by 728.0% in the second quarter. Acadian Asset Management LLC now owns 9,381 shares of the company’s stock valued at $111,000 after buying an additional 8,248 shares in the last quarter. 91.03% of the stock is currently owned by institutional investors and hedge funds.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.